20-02-2020
Ascannio / Shutterstock.com
Trade unions and consumer groups have urged the Federal Trade Commission (FTC) to intervene in the planned $63 billion merger of drugmakers AbbVie and Allergan, arguing it would “substantially harm competition”.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AbbVie, Allergan, US Federal Trade Commission, FTC, antitrust, competition, brazikumab, divestiture, rebate walls, merger
